Chief Executive Officer

Dr. Pelled is a senior biopharmaceutical executive with over two decades of experience in drug development. Before co-establishing INDoors Medical Development, he served for 5 years as the Chief Operating Officer at IMEL Biotherapeutics that develops cell-based therapy for the treatment of genetic diseases & age-related indications. Previously, he was the Vice President of Research & Development at the rare genetic diseases company Eloxx Pharmaceuticals (NASDAQ:ELOX). Earlier, he was Director of Preclinical Research at the orphan indications company Chiasma Pharmaceuticals (NASDAQ:CHMA; acquired by Amryt Pharma, NASDAQ: AMYT) and Chief Technology Officer and Director of Clinical Development at the lipid-based products company Enzymotec (NASDAQ:ENZY; acquired by Frutarom, LSE:FRUT/TASE:FRUT). Dr. Pelled earned his MSc and BSc degrees in Clinical Biochemistry and Chemistry from Tel-Aviv University, Israel, and PhD in Biochemistry from the Weizmann Institute of Science, Israel. He is a co-author of 25 peer reviewed publications and co-inventor of 17 patents